Diabetic neuropathy (DN) is one of the most common complications of diabetes and occurs when nerve fibers are damaged by prolonged exposure to elevated levels of blood glucose. People suffering from DN often feel pain or burning sensations in their extremities, followed by numbness, ulceration and eventual limb damage and even amputation. Over 50% of all people diagnosed with diabetes will suffer from diabetic neuropathy and it is estimated that, worldwide, over 374 million people have diabetes. Furthermore, those people most susceptible come from low- and middle-income countries where poor nutrition is prevalent.
There is no cure for diabetic neuropathy and most treatments focus on slowing disease progression, relieving pain and managing complications. Although tight glucose control and exercise can help reduce diabetic neuropathy in Type 1 (autoimmune) Diabetics, Type 2 sufferers (insulin resistance / deficiency) experience only modest improvements. Diabetic neuropathy affects all peripheral nerves including pain fibers, motor neurons and the autonomic nervous system. The burden of diabetic neuropathy for the patient is very significant with symptoms including numbness and tingling of extremities, burning or electric pain, vision changes, dizziness, muscle weakness, speech impairment, and fasciculation (muscle contractions). No therapy is available that could reverse or even stop progression.
ReMedys is working in cooperation with Relief Therapeutics SA on the development of an innovative therapeutic that holds promise to stop and possibly reverse loss of nerves and make real difference for suffering patients.